Wordt geladen...
Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
Advances in therapies have led to the approval of six therapeutic agents since 2004, each demonstrating overall survival benefit in randomized studies, and these have significantly improved the outlook for men facing metastatic castration-resistant prostate cancer (CRPC). More recently, efforts have...
Bewaard in:
| Gepubliceerd in: | Onco Targets Ther |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5905496/ https://ncbi.nlm.nih.gov/pubmed/29695920 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S147168 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|